Literature DB >> 19914975

Breast-specific gamma-imaging: molecular imaging of the breast using 99mTc-sestamibi and a small-field-of-view gamma-camera.

Elizabeth A Jones1, Trinh D Phan, Deborah A Blanchard, Abbe Miley.   

Abstract

Breast-specific gamma-imaging (BSGI), also known as molecular breast imaging, is breast scintigraphy using a small-field-of-view gamma-camera and (99m)Tc-sestamibi. There are many different types of breast cancer, and many have characteristics making them challenging to detect by mammography and ultrasound. BSGI is a cost-effective, highly sensitive and specific technique that complements other imaging modalities currently being used to identify malignant lesions in the breast. Using the current Society of Nuclear Medicine guidelines for breast scintigraphy, Legacy Good Samaritan Hospital began conducting BSGI, breast scintigraphy with a breast-optimized gamma-camera. In our experience, optimal imaging has been conducted in the Breast Center by a nuclear medicine technologist. In addition, the breast radiologists read the BSGI images in correlation with the mammograms, ultrasounds, and other imaging studies performed. By modifying the current Society of Nuclear Medicine protocol to adapt it to the practice of breast scintigraphy with these new systems and by providing image interpretation in conjunction with the other breast imaging studies, our center has found BSGI to be a valuable adjunctive procedure in the diagnosis of breast cancer. The development of a small-field-of-view gamma-camera, designed to optimize breast imaging, has resulted in improved detection capabilities, particularly for lesions less than 1 cm. Our experience with this procedure has proven to aid in the clinical work-up of many of our breast patients. After reading this article, the reader should understand the history of breast scintigraphy, the pharmaceutical used, patient preparation and positioning, imaging protocol guidelines, clinical indications, and the role of breast scintigraphy in breast cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914975     DOI: 10.2967/jnmt.109.063537

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  6 in total

1.  Implementation and evaluation of an expectation maximization reconstruction algorithm for gamma emission breast tomosynthesis.

Authors:  Zongyi Gong; Kelly Klanian; Tushita Patel; Olivia Sullivan; Mark B Williams
Journal:  Med Phys       Date:  2012-12       Impact factor: 4.071

2.  Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI.

Authors:  T Meissnitzer; A Seymer; P Keinrath; J Holzmannhofer; C Pirich; K Hergan; M W Meissnitzer
Journal:  Br J Radiol       Date:  2015-04-17       Impact factor: 3.039

3.  Retrospective and comparative analysis of (99m)Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women.

Authors:  Xiuyan Yu; Guoming Hu; Zhigang Zhang; Fuming Qiu; Xuan Shao; Xiaochen Wang; Hongwei Zhan; Yiding Chen; Yongchuan Deng; Jian Huang
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

4.  The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.

Authors:  Angela Collarino; Renato A Valdés Olmos; Lotta G A J van Berkel; Peter A Neijenhuis; Lidy M H Wijers; Frederik Smit; Lioe-Fee de Geus-Oei; Lenka M Pereira Arias-Bouda
Journal:  Breast Cancer Res Treat       Date:  2018-02-13       Impact factor: 4.872

5.  Comparison of 99mTc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions.

Authors:  Hongbiao Liu; Hongwei Zhan; Da Sun
Journal:  BMC Cancer       Date:  2020-05-24       Impact factor: 4.430

6.  Contrast-noise-ratio (CNR) analysis and optimisation of breast-specific gamma imaging (BSGI) acquisition protocols.

Authors:  Dennis Dickerscheid; Jules Lavalaye; Leo Romijn; Jan Habraken
Journal:  EJNMMI Res       Date:  2013-03-25       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.